You are here

FDA Approves IV Immune Globulin, Bivigam, for Immunodeficiency

Safety and efficacy demonstrated in phase III study (Dec. 20)

In a pivotal phase III, open-label trial –– published in the Journal of Clinical Immunology –– Bivigam successfully achieved its primary endpoints for safety, efficacy, and tolerability. In the study, a total of 63 patients with primary immunodeficiency were treated every 3 or 4 weeks with Bivigam infusions of 254 to 1,029 mg/kg (mean dose: 500 mg/kg) for approximately 1 year.

Fifty-nine patients (94%) reported at least one adverse event (AE). Of these patients, 40 (64%) were judged to have experienced an AE that was related to the study drug. Mild AEs occurred in 11 patients (18%); moderate AEs occurred in 21 patients (33%); and severe AEs occurred in 8 patients (13%). The most frequent severe, drug-related AEs were headache (three patients, 5%), migraine (two patients, 3%), and fatigue (two patients, 3%).

Two serious bacterial infections (SBIs) occurred during the study. Both patients were hospitalized. These two episodes resulted in an SBI rate of 0.035 SBI/patient/year –– substantially below the FDA’s target rate of = 1.0 SBI/patient/year.

The mean half-life of Bivigam was approximately 30 days.

Bivigam is a sugar-free, glycine-stabilized IVIG. The drug is available in 50-mL (5-gram) and 100-mL (10-gram) vials.

Sources: Biotest Pharmaceuticals; December 20, 2012; and Journal of Clinical Immunology; March 6, 2012.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed